The Relationship Between Payer and Risk of Surgical Site Infection Following Cesarean Delivery

Sarah H. Yi, Centers for Disease Control and Prevention
Kiran Mayi Perkins, Centers for Disease Control and Prevention
Sophia Kazakova, Centers for Disease Control and Prevention
Kelly Hatfield, Emory University
David Kleinbaum, Emory University
James Baggs, Emory University
Rachel B. Slayton, Emory University
John A. Jernigan, Emory University

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: Oxford University Press (OUP) | 2017-10-04, Pages S650-S650
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/ofid/ofx163.1731
Permanent URL: https://pid.emory.edu/ark:/25593/s6gc5

Final published version: http://dx.doi.org/10.1093/ofid/ofx163.1731

Copyright information:
© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed August 18, 2019 9:36 PM EDT
Background. There is limited data on incidence of MDROs colonization and corresponding elective surgical outcomes. Methods. We performed MDROs surveillance screening (swabs from nose, throat, groin, and rectum) in patients undergoing elective orthopedic surgery at the Thammasat University Hospital between March and August 2016. MDROs were defined as Gram-negative bacteria (GNB) possessing extended-spectrum β-lactamases (ESBLs), Carbapenem-resistant Enterobacteriaceae (CRE), and non-lactose fermenting GNB resistant to at least 3 antibiotic classes, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant enterococci (VRE). MDROs were identified by the Vitek®2 automated system. Antimicrobial susceptibility testing (disk diffusion test) was performed using the CLSI Interpretive Guidelines. Incidence of MDROs colonization upon admission was determined. Patient's clinical characteristics, risk factors for MDROs infection, procedure types and antibiotic prophylaxis were prospectively collected. Surgical sites infections (SSIs) and complications up to 6 months after surgery among the patients with and without MDROs colonization were compared.

Results. Of 384 swabs tested from 96 patients (median age, 58 years), ESBL-producing Escherichia coli (ESBL-E. coli) was identified in 31 rectal swabs (32.3%) and 7 (1.7%) were diagnosed with SSIs. A higher rate of SSIs was found among patients with ESBL-E. coli colonization (6/31, 19.4%), compared with patient without ESBL-E. coli colonization (1/65, 1.5%; P = 0.004, OR 15.4, 95% CI 1.7–356.3). From the multivariate logistic regression analysis, SSIs were significantly associated with ESBL-E. coli colonization (P = 0.009, adjusted OR 18.3, 95% CI 2.1–162.9). In addition, from the multivariate logistic regression analysis, ESBL-E. coli was a significantly risk factor associated with SSIs (6/7, 85.7%; P = 0.014, adjusted OR 16.5, 95% CI 1.8–153.4).

Conclusion. For the first time, we demonstrated a high incidence of ESBL-E. coli colonization and rate of SSIs in patients who had elective orthopedic surgery. These patients did not have any other risk factors for MDROs infection. Active screening for colonization of ESBL-producing pathogens may be necessary to guide appropriate antibiotic prophylaxis to reduce rates of SSIs.

Disclosures. All authors: No reported disclosures.

2203. Serratia and Surgical Site Infections: Risk Factors and Epidemiology

John O’Horo, MD, MPH1,2; Sarah Bellows Mahler, RN3; Barbara Gardner, RN3; and Elie F. Berbari, MD, FIDSA4

1Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, 2Infectious Diseases, Mayo Clinic, Rochester, Minnesota, 3Mayo Clinic, Rochester, Minnesota, 4Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota

Session: 243. HAI: Surgical Site Infections
Saturday, October 7, 2017: 12:30 PM

Background. Serratia spp. have been associated with surgical site infection (SSI) outbreaks associated with specific providers, topical creams and contaminated saline products. Patient risk factors for developing infection with this organism have not been extensively studied. We sought to evaluate risk factors for Serratia SSI.

Methods. Cases of Serratia SSI occurring between 2012 and 2016 were identified via an infection control surveillance program. SSI was defined by National Healthcare Safety Network (NHSN) criteria. Controls were randomly selected individuals undergoing similar procedures during the same time frame without identified Serratia SSI. Data was analyzed using partitioning, student T test and chi-square analysis to identify risk factors for Serratia SSI.

Results. During the study period, 17 cases and 34 controls were identified, all of whom were cardiac or vascular surgery patients. Cases were affected far more often than females (Relative risk 4.9, 95% CI 0.72–33.37, P = 0.04) Cases were older (mean age [standard error] 55.1 [3.40] vs. 66.3 [3.42] years, P = 0.04), had longer operative times (238.1 [19.1] vs. 212.5 [28.2] minutes, P = 0.04), and a similar American Society of Anesthesiologists preoperative risk score (3.8 [0.07] vs. 3.1 [0.07], P = 0.83). We did not observe significant differences in body mass index, cardiopulmonary comorbidities, preoperative catherization, or malignancy. In partition analysis, gender, (incision time >180 minutes and age >62) was all highly predictive of Serratia SSI risk (receiver operator characteristic 0.81). Other risk factors screened, including types of vascular access, specific surgeon(s) performing procedures, reoperation, open chest procedures and antecedent cardiac catheterization, were not significantly associated with an increased risk of serratia SSI’s. Serratia SSI’s were associated with a 29% 30-day mortality rate, compared with 5.8% seen in controls (P = 0.02).

Conclusion. Gender, operative time and age are associated with an increase in Serratia SSI risk. Serratia SSI is associated with a high mortality rate. Providers should be vigilant for this organism, particularly in older male patients undergoing complex cardiac or surgical procedures.

Disclosures. All authors: No reported disclosures.

2204. The Relationship Between Payer and Risk of Surgical Site Infection Following Cesarean Delivery

Sarah H. Yi, PhD1; Kiran Mayi Perkins, MD, MPH2; Sophia Kazakova, MD, MPH, PhD3; Kelly Hatfield, MSPH4; David Kleinbaum, PhD5,6; James Baggs, PhD7; Rachel B. Skylton, PhD, MPH8; and John A. Jernigan, MD, MS9

1Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, 2Rollins School of Public Health, Department of Epidemiology, Emory University, Atlanta, Georgia

Session: 243. HAI: Surgical Site Infections
Saturday, October 7, 2017: 12:30 PM

Background. Both Medicaid and private health insurance support important access to care for many pregnant women in the United States. The role of health insurance on many outcomes, such as surgical site infection (SSI) following Cesarean delivery (CD), has not been adequately studied.

Methods. This retrospective cohort study investigated SSI risk following CD performed in California hospitals in 2011 among women covered by Medicaid or private health insurance. All CD were obtained from identifiable state inpatient outpatient hospital data and linked with National Healthcare Safety Network (NHSN) data to ascertain post-delivery SSI. Characteristics including age, race/ethnicity, BMI, prior CD planned admission, emergency CD, active labor and labor duration, ASA physical status, general anesthesia, wound class, hospital ownership, hospital annual CD count, intercontinental travel, body mass index, comorbidities, and discharge diagnosis were included in the analysis.

Results. A higher SSIs rate was found among Medicaid insured women compared with privately insured women (odds ratio [OR] 2.1, 95% confidence interval [CI] 1.2–3.6). We observed a trend in increased SSI risk compared with women with private insurance. There were no differences in adjusted SSIs risk by payer in government (OR: 1.1, 95% CI 0.7–1.8, P = 0.92) or not-for-profit hospitals (OR: 0.9, 95% CI 0.5–1.2, P = 0.52).

Conclusion. Despite accounting for various patient and facility-level factors, Medicaid-insured women experienced higher SSI risk than privately-insured women in for-profit hospitals, but not in government owned or not-for-profit hospitals. Additional studies to understand underlying causes may help target efforts to prevent SSI following CDs among vulnerable patients.

Disclosures. All authors: No reported disclosures.

2205. Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis

Saturday, October 7, 2017: 12:30 PM

Background. Current practice guidelines non-preferentially recommend cefazolin, cefoxitin, cefotetan, or amoxicillin-clavulanate as first line choices for antibiotic prophylaxis in hysterectomy. We undertook a systematic review to determine whether cefazolin, with no anti-anaerobic activity, is as effective as β-lactam antibiotics with anti-anaerobic activity at preventing surgical site-infection (SSI) after abdominal or vaginal hysterectomy.

Methods. We searched PubMed, Scopus, Web of Science, Cochrane Central, and conference proceedings for randomized controlled trials (RCT) in any language up to May 16, 2016. Main search terms included cephalosporins, antibiotic prophylaxis, hysterectomy, surgical wound infection, clinical trials, and random allocation. We included only RCT that measured SSI – surgical site infection, superficial, deep, or organ space. We excluded trials of β-lactams no longer in clinical use. We used predefined data extraction templates, including bias assessment indicators, and performed meta-analyses with random-effects models.

Results. Fourteen RCTs met inclusion criteria. There were 98 (5%) SSI among 1,903 patients in the cefazolin group, and 78 (4%) SSI among 1,772 patients in the comparator β-lactam (cefoxitin, cefotetan, cefotaxime, ceftriaxone, amoxicillin, amoxicillin/clavulinate, or penicillin) group. The summary estimate showed no significant benefit for cefazolin vs. other β-lactam in reducing SSI (Risk Ratio 1.19; 95% CI 0.88–1.62, P = 0.23). Cefazolin had a higher SSI risk when compared with cefoxitin, cefotetan, or amoxicillin/clavulanate (Risk Ratio 1.56; 95% CI 1.25–5.4, P = 0.01). We observed no differences in adjusted SSI risk compared with women with private insurance.

Conclusion. Despite accounting for various patient and facility-level factors, Medicaid-insured women experienced higher SSI risk than privately-insured women in for-profit hospitals, but not in government owned or not-for-profit hospitals. Additional studies to understand underlying causes may help target efforts to prevent SSI following CDs among vulnerable patients.

Disclosures. All authors: No reported disclosures.